載入中
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
前收盤價
US$130.9
+US$4.27 · +3.37%
盤中時間採用ET。市場資料可能有所延遲。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日內區間
目前US$130.9
52週區間
目前US$130.9
盤中時間採用ET。市場資料可能有所延遲。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日內區間
目前US$130.9
52週區間
目前US$130.9
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 |
|---|---|---|---|
| 研究與開發 | 6206.5萬 USD | 2328.3萬 USD | 1497.1萬 USD |
| 銷售、一般及管理費用 | 1028.2萬 USD | 349.5萬 USD | 235.3萬 USD |
| 營業費用 | 7234.7萬 USD | 2677.8萬 USD | 1732.4萬 USD |
| 利息收入 | 156.2萬 USD | 48.1萬 USD | 87萬 USD |
| 利息支出 | — | 58.5萬 USD | 3.6萬 USD |
| 營業利益 | −7234.7萬 USD | −2677.8萬 USD | −1732.4萬 USD |
| 淨利 | −6999.5萬 USD | −2648.8萬 USD | −1649萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$162.67
上漲空間 24.27%評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM7343.97萬0.09%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI6100.28萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF2294.03萬0.02%954億 USD0.05%US$235+0.80%
JPMorgan Active Growth ETFJGRO2164.37萬0.21%102.21億 USD0.44%US$98.31+0.92%
Schwab U.S. Small-Cap ETFSCHA2099.73萬0.10%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO1778.72萬0.13%139.17億 USD0.24%US$356.78+0.94%
iShares U.S. Pharmaceuticals ETFIHE1381.14萬0.90%15.52億 USD0.37%US$100.09+1.24%
Vanguard Russell 2000 ETFVTWO1231.04萬0.07%180億 USD0.06%US$112.66+0.50%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFJPMorgan Active Growth ETFJGROSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
